JP2006505564A5 - - Google Patents

Download PDF

Info

Publication number
JP2006505564A5
JP2006505564A5 JP2004544891A JP2004544891A JP2006505564A5 JP 2006505564 A5 JP2006505564 A5 JP 2006505564A5 JP 2004544891 A JP2004544891 A JP 2004544891A JP 2004544891 A JP2004544891 A JP 2004544891A JP 2006505564 A5 JP2006505564 A5 JP 2006505564A5
Authority
JP
Japan
Prior art keywords
use according
sarm
nhcor
conhr
snr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004544891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/032513 external-priority patent/WO2004035739A2/en
Publication of JP2006505564A publication Critical patent/JP2006505564A/ja
Publication of JP2006505564A5 publication Critical patent/JP2006505564A5/ja
Pending legal-status Critical Current

Links

JP2004544891A 2002-10-16 2003-10-14 Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療 Pending JP2006505564A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41833602P 2002-10-16 2002-10-16
PCT/US2003/032513 WO2004035739A2 (en) 2002-10-16 2003-10-14 Treating androgen decline in aging male (adam)-associated conditions with sarms

Publications (2)

Publication Number Publication Date
JP2006505564A JP2006505564A (ja) 2006-02-16
JP2006505564A5 true JP2006505564A5 (enExample) 2006-08-17

Family

ID=32107914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544891A Pending JP2006505564A (ja) 2002-10-16 2003-10-14 Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療

Country Status (9)

Country Link
US (1) US20050080054A1 (enExample)
EP (1) EP1558233A2 (enExample)
JP (1) JP2006505564A (enExample)
CN (1) CN1726020A (enExample)
AU (1) AU2003287079A1 (enExample)
CA (1) CA2501874A1 (enExample)
IL (1) IL168046A0 (enExample)
TW (1) TW200502250A (enExample)
WO (1) WO2004035739A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20060019931A1 (en) * 2003-10-14 2006-01-26 Dalton James T Treating bone-related disorders with selective androgen receptor modulators
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
DE602005024274D1 (de) 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US8791158B2 (en) 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
JP6055215B2 (ja) 2012-06-29 2016-12-27 キーサイト テクノロジーズ， インク． インピーダンス測定方法及び測定装置
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CA3002562A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN114599369B (zh) 2019-06-03 2026-02-10 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法
CN122228246A (zh) * 2023-11-16 2026-06-16 恩多凯医药科技（北京）有限公司 神经活性雄激素受体调节剂及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6569896B2 (en) * 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
AU7604798A (en) * 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) * 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) * 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20060019931A1 (en) * 2003-10-14 2006-01-26 Dalton James T Treating bone-related disorders with selective androgen receptor modulators
PT1463497E (pt) * 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
CA2689080C (en) * 2002-02-07 2011-07-05 University Of Tennessee Research Foundation Treating benign prostate hyperplasia with sarms
AU2003287075A1 (en) * 2002-10-15 2004-05-04 Gtx, Inc. Treating obesity with selective androgen receptor modulators
EP1594490A4 (en) * 2003-01-22 2006-03-22 Gtx Inc TREATMENT OF WOMEN ANDROGEN DISEASE ASSOCIATED DISORDERS (ADIF) USING ANDROGENIC RECEPTOR MODULATORS (SARM)

Similar Documents

Publication Publication Date Title
JP2006511486A5 (enExample)
JP2006516286A5 (enExample)
JP2006518328A5 (enExample)
JP2006514098A5 (enExample)
JP2009506119A5 (enExample)
RU2015104780A (ru) Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm)
JP2006506369A5 (enExample)
US7772433B2 (en) SARMS and method of use thereof
JP2005526741A5 (enExample)
AU2008239601B2 (en) Selective androgen receptor modulators for treating diabetes
US8110562B2 (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CA2538095A1 (en) Selective androgen receptor modulators and methods of use thereof
CA2477737A1 (en) Multi-substituted selective androgen receptor modulators and methods of use thereof
US20130034562A1 (en) Selective androgen receptor modulators for treating diabetes
JP2006505563A (ja) 選択的アンドロゲン受容体調節剤による肥満治療
CA2621189A1 (en) Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CA2832598A1 (en) Selective androgen receptor modulators for treating diabetes
CA2535953A1 (en) Treating bone-related disorders with selective androgen receptor modulators
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
CA2551737A1 (en) Helix 12 directed steroidal pharmaceutical products
WO2004064747A2 (en) Treating androgen deficiency in female (adif)-associated conditions with sarms
JP2007513998A5 (enExample)
RU2015147509A (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
US10662148B2 (en) Selective androgen receptor modulator and methods of use thereof